Finance

Lists
Q2 2026 earnings • released • EPS beat +110.90% • Revenue miss -0.21%
See results
A1ZN34:BVMF
Astrazeneca Plc Bdr
R$148.07
+0.59%
(+0.87) 1D
Jul 29, 3:46:22 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for A1ZN34...
Open
R$148.00
High
R$149.01
Low
R$148.00
Mkt. cap
268.22B
Avg. vol.
185.00
Volume
75.00
52-wk high
R$190.40
52-wk low
R$130.02
Shares outstanding
1.55B
No. of employees
96K
Open
R$148.00
High
R$149.01
Low
R$148.00
Mkt. cap
268.22B
Avg. vol.
185.00
Volume
75.00
52-wk high
R$190.40
52-wk low
R$130.02
Shares outstanding
1.55B
No. of employees
96K
News stories
From sources across the web
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US. AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About Astrazeneca Plc Bdr
CEOPascal Soriot
Employees96.1K
FoundedApr 6, 1999
HeadquartersCambridge, Cambridgeshire, United Kingdom
SectorPharmaceutical industry
Websiteastrazeneca.com
Last report
Jul 27, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$2.63 / $1.25
+110.90%beat
Revenue / Est. (USD)
15.38B / 15.42B
-0.21%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
15.19B
15.50B
15.29B
15.38B
Cost of goods sold
2.79B
3.17B
2.67B
-
Cost of revenue
2.79B
3.17B
2.67B
-
Research and development expenses
3.63B
3.62B
3.47B
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.20B
5.32B
5.03B
-
Operating expense
8.74B
8.99B
8.34B
-
Total operating expenses
11.53B
12.16B
11.02B
-
Operating income
3.66B
3.35B
4.27B
-
Other non operating income
-
-247.00M
-
-
EBT including unusual items
3.24B
2.63B
3.91B
-
EBT excluding unusual items
3.32B
3.05B
3.94B
-
Income tax expense
709.00M
300.00M
833.00M
-
Effective tax rate
21.86%
11.41%
21.28%
-
Other operating expenses
-89.00M
53.00M
-155.00M
-
Net income
2.53B
2.33B
3.08B
-
Net profit margin
16.67%
15.00%
20.15%
-
Earnings per share
2.38
2.12
1.29
2.63
Interest and investment income
85.00M
135.00M
73.00M
-
Interest expense
-434.00M
-155.00M
-393.00M
-
Net interest expenses
-349.00M
-20.00M
-320.00M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
5.21B
4.11B
5.64B
-
Gain or loss from assets sale
-31.00M
-37.00M
-34.00M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer